ArticleHaematologica2012

Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.

Cesar Homero Gutiérrez-Aguirre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.